Renal outcomes in valve-in-valve transcatheter versus redo surgical aortic valve replacement: A systematic review and meta-analysis.
Arian Arjomandi RadVinci NarukaRobert VardanyanMohammad Yousuf SalmasiPanagiotis T TasoudisSimon KendallRoberto CasulaThanos AthanasiouPublished in: Journal of cardiac surgery (2022)
Renoprotective strategies should be put into place to prevent and reduce AKI incidence regardless of the treatment modality. Patients undergoing re-intervention for the aortic valve constitute a high-risk and frail population in which ViV-TAVR demonstrated it might be a feasible option for carefully selected patients. Long-term follow-up data and randomized control trials will be needed to evaluate mortality and morbidity outcomes between these 2 treatments.
Keyphrases
- aortic valve
- aortic valve replacement
- aortic stenosis
- ejection fraction
- transcatheter aortic valve implantation
- transcatheter aortic valve replacement
- patients undergoing
- end stage renal disease
- newly diagnosed
- randomized controlled trial
- risk factors
- left ventricular
- chronic kidney disease
- acute kidney injury
- phase iii
- cardiovascular events
- double blind
- peritoneal dialysis
- coronary artery disease
- heart failure
- prognostic factors
- big data
- adipose tissue
- insulin resistance
- mitral valve